UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): January 18, 2013
Verastem, Inc.
(Exact Name of Registrant as Specified in Charter)
|
Delaware |
|
001-35403 |
|
27-3269467 |
|
(State or Other Jurisdiction of Incorporation) |
|
(Commission |
|
(IRS Employer |
|
215 First Street, Suite 440, Cambridge, MA |
|
02142 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (617) 252-9300
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 18, 2013, Verastem, Inc. (the “Company”) appointed Robert Forrester as President of the Company. Mr. Forrester will continue to serve as Chief Operating Officer of the Company. Christoph Westphal, M.D., Ph.D. previously served as President and will remain Chief Executive Officer of the Company.
Mr. Forrester, 49, has served as Chief Operating Officer of the Company since March 2011. Prior to joining the Company, Mr. Forrester served as Chief Operating Officer of Forma Therapeutics, Inc. from 2010 until 2011. Previously he served as Interim President and Chief Executive Officer of CombinatoRx, Inc., now Zalicus Inc., from 2009 until 2010 and as its Executive Vice President and Chief Financial Officer from 2004 to 2009. Mr. Forrester served as Senior Vice President, Finance and Corporate Development at Coley Pharmaceuticals Group, Inc. from 2000 to 2003. Mr. Forrester is a member of the Board of Directors of Myrexis Pharmaceuticals.
A copy of the press release discussing these changes is filed as Exhibit 99.1 hereto.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
VERASTEM, INC. | |
|
|
| |
|
|
| |
|
Date: January 22, 2013 |
By: |
/s/ Paul Brannelly |
|
|
|
Paul Brannelly |
|
|
|
Vice President, Finance |